Loading... Please wait...
Sort by:

FirstWord Generics/Biosimilar Reports

 

  • Pricing and Reimbursement in Respiratory: Payer Views [2020]
    Learn More Pricing and Reimbursement in Respiratory: Payer Views [2020]
    How have payers met the challenge of COVID-19 and how do they see the future? The impact of the COVID-19 pandemic has been especially felt in respiratory disease and presents a unique set of challenges for payers. From...
  • Innovations in Drug Pricing and Reimbursement 2020
    Learn More Innovations in Drug Pricing and Reimbursement 2020
    Evaluating new digital tools and deal structures to drive better commercial outcomes What are the trends and technologies that could deliver a better understanding of payers' needs and build improved evidence of value?...
  • Data Driven Customer Relationship Management In Pharma
    Learn More Data Driven Customer Relationship Management In Pharma
    Experts agree data-driven CRM holds the key to achieving true customer centricity It's already known that data-driven CRM improves and drives forward the customer experience. Pharma has a powerful tool at its disposal,...
  • Real World Data for Orphan Drugs: Meeting the Data Analysis Challenge
    Learn More Real World Data for Orphan Drugs: Meeting the Data Analysis Challenge
    Creating meaningful insights from diverse data sources The explosion in real-world data (RWD) from digital platforms is creating new insights into the understanding of rare diseases and patient experiences. The value...
  • Trends in KOL Experience Management [2020]
    Learn More Trends in KOL Experience Management [2020]
    Is your MSL team delivering an outstanding KOL experience? KOL support and insights are critical to pharma, and MSLs are charged with delivering a service that keeps them fully informed and engaged. But how do you...
  • Pricing and Reimbursement in Neurology: Payer Views  [2020]
    Learn More Pricing and Reimbursement in Neurology: Payer Views [2020]
    Understanding payer challenges in Multiple Sclerosis, Epilepsy, Migraine and Neurodegenerative disease Despite wide unmet need across a number of neurological conditions, no really high impact breakthrough therapies...
  • Value-based Healthcare in a Digital World [2020]
    Learn More Value-based Healthcare in a Digital World [2020]
    Accelerated use of digital technology challenges pharma to rethink its approach COVID-19 has radically increased the use of digital technology by patients and HCPs but how does that play into the trend to value-based...
  • Orphan Drugs: Benchmarking Commercial Models [2020]
    Learn More Orphan Drugs: Benchmarking Commercial Models [2020]
    What are the essential factors for orphan drug success? Several orphan drugs have proven to be commercial winners, so what are the key ingredients for success in 2020? For example, as the sector has evolved the power...
  • MSL-KOL Engagement [2020]
    Learn More MSL-KOL Engagement [2020]
    Maintaining and growing KOL relationships in pandemic lockdown At a stroke, the COVID-19 pandemic shut down MSL's principal KOL engagement channels. With face-to-face interactions on hold, MSLs have turned to...
  • The Rise of ICER – The Payer Perspective
    Learn More The Rise of ICER – The Payer Perspective
    Payers reveal where ICER is really impacting pharma/payer relations How is the Institute for Clinical and Economic Review (ICER) influencing payer behavior? ICER's evidence and price benchmarking data are valued by...
  • The State of Pharma Digital Transformation 2020
    Learn More The State of Pharma Digital Transformation 2020
    How far has pharma come, and what does it still need to do, to realize the full benefits of digital technology across its business? The COVID-19 pandemic may have spurred rapid expansion in the use of digital tools but...
  • Smart Pharma Sales: How Digital is Reinventing the Process
    Learn More Smart Pharma Sales: How Digital is Reinventing the Process
    Post COVID-19, pharma's opportunity is to build on the impact of digital technology to revolutionize its sales practice and engagement strategies The COVID-19 pandemic has radically reshaped how pharma does sales and...
  • Engaging with ICER: Lessons and insights for pharma
    Learn More Engaging with ICER: Lessons and insights for pharma
    ICER is here to stay so how best can industry engage for its benefit? The Institute for Clinical and Economic Review (ICER) is gaining a growing reputation with US payers. While ICER's drug assessments are advisory, and...
  • Digital Health and the Management of Chronic Disease
    Learn More Digital Health and the Management of Chronic Disease
    Essential strategies for developing next phase digital health solutions The COVID-19 pandemic has accelerated and elevated the role of digital health and could serve as a turning point for digital platforms to become...
  • Measuring Digital Success in Pharma: Essential KPIs
    Learn More Measuring Digital Success in Pharma: Essential KPIs
    Which KPI's should pharma be using to assess the success of its digital technology investments? The Covid-19 pandemic is fundamentally changing working practice and driving immediate expansion of digital solutions. But...
  • Biosimilars: US Payer Insights 2020
    Learn More Biosimilars: US Payer Insights 2020
    What do payers see as unlocking the sluggish US biosimilar market? Despite the availability of biosimilar versions of Avastin, Herceptin and Rituxan, payers are not pleased with the development within this sector...
  • Drivers of Non-medical Rx Switching
    Learn More Drivers of Non-medical Rx Switching
    The strategies that are promoting wider use of biosimilars Payers are highly motivated to realise the cost savings of biosimilars, but what strategies are they using to reassure and encourage physicians and patients?...
  • Trends in Digital Physician Engagement
    Learn More Trends in Digital Physician Engagement
    Next level opportunities for developing physician relationships across pharma's business Digital technology has transformed pharma's communications with often difficult to engage physicians. But merely having a suite of...
  • Trends in Digital Patient Engagement
    Learn More Trends in Digital Patient Engagement
    Embedding digital patient engagement throughout the patient journey Pharma companies have made good progress with digital delivery within innovative patient support programs—but there is still significant scope to...
  • Biosimilars: Go-to-Market Case Studies
    Learn More Biosimilars: Go-to-Market Case Studies
    As the biosimilar sector matures, what are the key issues that are shaping commercial strategies? As physician and payer confidence in the use of biosimilars grows, US and European companies are having to rethink their...

customer.service@firstwordpharma.com

All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved